Gemcitabine (2’-deoxy-2’-difluorode

Gemcitabine (2'-deoxy-2'-difluorodeoxycytidine: Gemzar) (GEM) appears to be the onlyeffective anticancer drug for pancreatic cancer, but it has littleimpact on outcome due to a high level of inherent and acquiredtumor resistance. Our previous proteomic study demonstratedthat the expression of three spots of heat-shock protein 27(HSP27) was increased in GEM-resistant pancreatic cancer cellsand could play a role in determining the sensitivity of pancreaticcancer to GEM. Materials and Methods and Results: In thepresent study, using one-dimensional and two-dimensionalWestern blotting, we elucidated that these three spots of HSP27were phosphorylated in GEM-resistant pancreatic cancer cellline, KLM1-R. Conclusion: Phosphorylated HSP27 may play animportant role in the resistance to GEM, and it could also be apossible biomarker for predicting the response of pancreaticcancer patients to treatment with GEM

Gemcitabine (2 '- deoxy-2' -
difluorodeoxycytidine: Gemzar) (GEM) appears to be the only
effective anticancer drug for pancreatic. Cancer but it, has little
impact on outcome due to a high level of inherent and acquired
tumor resistance. Our previous. Proteomic study demonstrated
that the expression of three spots of heat-shock protein 27
.(HSP27) was increased in GEM-resistant pancreatic cancer cells
and could play a role in determining the sensitivity of. Pancreatic
cancer to GEM. Materials and Methods and Results: In the
present study using one-dimensional, and two-dimensional
Western. Blotting we elucidated, that these three spots of HSP27
were phosphorylated in GEM-resistant pancreatic cancer cell
line,, KLM1-R. Conclusion:Phosphorylated HSP27 may play an
important role in the resistance, to GEM and it could also be a
possible biomarker for. Predicting the response of pancreatic
cancer patients to treatment with GEM.